Taizhou Crene Biotechnology Co., Ltd.
                                                                                                           
Verified Supplier
19 Years
Since 2007
Menu
Fabrication Services Other Fabrication Services

API-1 NSC 177223 Custom Chemical Synthesis Cas 36707-00-3

Price Negotiable
Price: Negotiable
MOQ: 1g
Delivery Time: Negotiable
Brand: Crene
Product Description

API-1 NSC 177223 Custom Chemical Synthesis Cas 36707-00-3

 

Chemical Information
Product name:API-1 NSC 177223 Purity:98% min
CAS NO:36707-00-3 Solubility:
Molecular Formula:C13H15N5O6 Package:Package according to customer requirements
Molecular Weight:337.28 Storage:-20℃
Remarks

API-1 is a potent Akt inhibitor, which induces GSK3-dependent, β-TrCP- and FBXW7-mediated Mcl-1 degradation, resulting in induction of apoptosis . API-1 rapidly and potently reduced the levels of Mcl-1 primarily in API-1-senstive lung cancer cell lines. Ectopic expression of Mcl-1 protected cells from induction of apoptosis by API-1. API-1 treatment decreased the half-life of Mcl-1, whereas inhibition of the proteasome with MG132 rescued Mcl-1 reduction induced by API-1. API-1 decreased Mcl-1 levels accompanied with a rapid increase in Mcl-1 phosphorylation (S159/T163). Moreover, inhibition of GSK3 inhibited Mcl-1 phosphorylation and reduction induced by API-1 and antagonized the effect of API-1 on induction of apoptosis.

References
1: Ren H, Koo J, Guan B, Yue P, Deng X, Chen M, Khuri FR, Sun SY. The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis. Mol Cancer. 2013 Nov 22;12:146. doi: 10.1186/1476-4598-12-146. PubMed PMID: 24261825.

Get in Touch

Have questions about our products or want to discuss a custom order? Our team is ready to help you.

Company Taizhou Crene Biotechnology Co., Ltd.
Location Add: Economic Developed Zone of Taizhou Zhejiang China.

Request A Quote

Please check your email address.
Your message must be at least 20 characters.